Weight Loss with Wegovy (Semaglutide 2.4 mg Weekly)
Patients taking Wegovy (semaglutide 2.4 mg weekly) achieve approximately 14.9–16.0% total body weight loss at 68 weeks, with nearly two-thirds (64.9%) losing ≥10% of their starting weight. 1
Expected Weight Loss Outcomes
Mean Weight Reduction
- Injectable semaglutide 2.4 mg weekly produces 14.9–16.0% mean weight loss at 68 weeks in adults with obesity or overweight without diabetes, compared to only 2.4–5.7% with placebo. 1, 2
- At 6 months, patients typically achieve 10–12% weight loss, with continued reduction through 68 weeks. 2
Proportion Achieving Weight Loss Thresholds
- 64.9% of patients achieve ≥10% weight loss at 68 weeks on semaglutide 2.4 mg weekly. 1
- 86.6% achieve ≥5% weight loss, which is the minimum threshold for clinically meaningful benefit. 1
- Approximately 21% achieve ≥10% weight loss in some trials, though the higher figure (64.9%) represents the most robust data. 3
Comparison to Other Formulations and Agents
Oral Semaglutide
- Oral semaglutide 25 mg daily produces 13.6% mean weight loss at 64 weeks, slightly less than the 2.4 mg weekly injection but still clinically meaningful. 4
- Oral semaglutide 50 mg daily achieves 15.1% mean weight loss at 68 weeks, comparable to injectable semaglutide 2.4 mg. 5
- Injectable formulations remain superior for most patients, but oral semaglutide offers an alternative for those who strongly prefer to avoid injections. 1
Tirzepatide (Dual GIP/GLP-1 Agonist)
- Tirzepatide 15 mg weekly produces 20.9% mean weight loss at 72 weeks, representing a 6% absolute advantage over semaglutide 2.4 mg. 1
- Nearly 40% of patients on tirzepatide 15 mg achieve ≥25% weight loss, exceeding semaglutide's efficacy. 1
Liraglutide
- Liraglutide 3.0 mg daily achieves only 5.2–6.1% mean weight loss, substantially less than semaglutide. 1, 2
Factors Influencing Weight Loss Response
Diabetes Status
- Weight loss is consistently greater in non-diabetic patients (6.1–17.4%) compared to those with type 2 diabetes (4.0–6.2%), suggesting metabolic factors and insulin resistance influence treatment response. 1, 2
Body Composition Changes
- Total fat mass decreases by 14% at 7 months and 18% at 12 months on semaglutide 2.4 mg. 6
- Lean mass initially declines by approximately 3 kg at 7 months but stabilizes thereafter, with handgrip strength improving by 4.5 kg at 12 months. 6
- The prevalence of sarcopenic obesity decreases from 49% at baseline to 33% at 12 months. 6
Sex Differences
- Women experience greater weight and fat mass loss than men on semaglutide. 1
Treatment Response Criteria
Defining Adequate Response
- Patients should achieve ≥5% weight loss after 3 months (12–16 weeks) on the maximum tolerated dose to justify continuation of therapy. 1
- If weight loss is <5% after 3 months, discontinue semaglutide and consider alternative approaches such as tirzepatide or metabolic surgery. 1
Early Responders
- Early responders (≥5% weight loss after 3 months) should continue long-term therapy, as they are likely to achieve further weight loss with sustained use. 1
Practical Considerations
Titration Schedule
- Start semaglutide at 0.25 mg weekly for 4 weeks, then increase every 4 weeks (0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg maintenance dose by week 17). 1
- Slow titration minimizes gastrointestinal adverse effects (nausea, vomiting, diarrhea), which occur in 53% of patients but are typically mild-to-moderate and transient. 1
Lifestyle Integration
- Semaglutide must be combined with a reduced-calorie diet (approximately 500-kcal daily deficit) and ≥150 minutes per week of moderate-intensity physical activity to optimize outcomes. 1
- Resistance training should be incorporated to preserve lean body mass during weight loss. 1
Long-Term Use
- Weight regain occurs after discontinuation, with patients regaining 50–67% of lost weight within one year of stopping therapy. 1, 2
- Lifelong treatment is typically necessary to maintain weight loss and metabolic benefits. 1
Safety Profile
Common Adverse Effects
- Gastrointestinal effects (nausea 18–40%, diarrhea ~12%, vomiting 8–16%) are the most frequent adverse events, occurring in a dose-dependent manner and usually resolving within 4–8 weeks. 1
Serious Adverse Events
- Serious adverse events occur 38% more frequently than with placebo (95% CI 1.10–1.73), including pancreatitis, cholelithiasis, and cholecystitis. 1
- Patients should be instructed to report persistent severe abdominal pain immediately. 1
Contraindications
- Absolute contraindication: personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN 2). 1
Cost Considerations
- A 30-day supply of semaglutide 2.4 mg costs approximately $1,557–$1,619, requiring long-term financial planning and insurance authorization. 1
- When long-term cardiovascular and metabolic benefits are accounted for, semaglutide is cost-effective at approximately $150,000 per quality-adjusted life year (QALY) gained. 1
Common Pitfalls to Avoid
- Do not declare treatment failure before reaching the 2.4 mg maintenance dose or before completing at least 12–16 weeks of therapy. 1
- Do not discontinue prematurely due to mild gastrointestinal side effects; these typically resolve with continued exposure and dietary adjustments. 1
- Do not assume weight loss will continue indefinitely without lifestyle modifications; semaglutide must be paired with sustained dietary and physical activity changes. 1